Clinical Pharmacokinetics

, Volume 24, Issue 6, pp 472–495

Cyclosporin Clinical Pharmacokinetics

  • Alfred Fahr
Review Article Drug Disposition

Summary

Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. It is a lipophilic molecule, with its bioavailability dependent on food, bile and other interacting factors. Cyclosporin is extensively metabolised in the liver by the cytochrome P450 3A system, which is subject to considerable interindividual variation.

Distribution of cyclosporin depends not only on physicochemical characteristics, but also on biological carriers such as lipoproteins and erythrocytes in blood. Cyclophilin, a binding protein for cyclosporin, influences distribution of cyclosporin in the body. Despite its lipophilicity, cyclosporin does not appear in the brain. The distribution of metabolites in the body can differ from that of cyclosporin itself Elimination of the drug is mainly via the bile as metabolites, other routes not being very important.

Pharmacokinetic parameters of cyclosporin are highly variable and depend on factors such as age, the physical condition of the patient, type of organ transplant or comedication. Renal side effects of cyclosporin are dose-related, but the influence of the dosage regimen has not been thoroughly investigated.

An important factor in the reported variability is the different analytical methods used. Following the recommendations of recent consensus documents to monitor blood concentrations, this source of variability may diminish in the future.

Several metabolites are reported as having less immunosuppressive activity than the parent drug. Metabolites with renal side effects have been reported. These and other effects of metabolites have not been clearly defined in the literature, presumably because of the highly variable activity of cyclosporin-metabolising liver enzymes and the paucity of data available on metabolite pharmacokinetics.

The therapeutic range and dosage of cyclosporin are therefore highly dependent on many individual parameters in patients. Dosages of less than 5 mg/kg/day, however, rarely cause renal side effects. Further studies to correlate the clinical pharmacokinetics of metabolites with their activity and adverse effects are needed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams DH, Ponsford S, Gunson B, Boon A, Honigsberger L, et al. Neurological complications following liver transplantation. Lancet 1: 949–951, 1987PubMedGoogle Scholar
  2. Albrechtsen D, Helgerud P, Jakobsen A, Rugstad HE. Blood and intestinal lymph cyclosporine levels in the rat after oral and intravenous medication. Transplantation Proceedings 18: 42–43, 1986Google Scholar
  3. Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R, et al. Oral administration of cyclosporin A for recipients of allogenic marrow transplants: implications of clinical gut dysfunction. British Journal of Haematology 56: 223–231, 1984PubMedGoogle Scholar
  4. Awni WM, Heim-Duthoy K, Anderson R, Kasiske BL. Time-dependent changes in the pharmacokinetics of cyclosporine and its metabolites in renal transplant patients. Journal of Pharmaceutical Science 76: S63, 1987Google Scholar
  5. Awni WM, Heim-Duthoy KL, Rao KV, Kasiske BL. Pharmacokinetics of cyclosporine and its M1, M17 and M21 metabolites in renal transplant patients over time. Clinical Pharmacology and Therapeutics 43: 198, 1988Google Scholar
  6. Awni MW, Sawchuk RJ. The pharmacokinetics of cyclosporine: I. Single dose and constant rate infusion studies in the rabbit. Drug Metabolism and Disposition 13: 127–132, 1985PubMedGoogle Scholar
  7. Bach JF. Cyclosporine in autoimmune diseases. Transplantation Proceedings 21 (Suppl. 1): 97–113, 1989PubMedGoogle Scholar
  8. Begley DJ, Squires LK, Zlokovic BV, Mitrovic DM, Hughes CCW, et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. Journal of Neurochemistry 55: 1222–1230, 1990PubMedGoogle Scholar
  9. Bernareggi B, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. Journal of Pharmacokinetics and Biopharmaceutics 19: 21–50, 1991PubMedGoogle Scholar
  10. Beveridge T, Gratwohl A, Michot F, Niederberger W, Nüesch E, et al. Cyclosporin A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone-marrow grafts. Current Therapeutic Research 30: 5–18, 1981Google Scholar
  11. Bolas-Fernandez F, Grencis RK, Wakelin D. Cyclosporin A and Trichinella spiralis: anthelmintic effects in immunosuppressed mice. Parasitic Immunology 10: 111–116, 1988Google Scholar
  12. Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents and Actions 6: 468–475, 1976PubMedGoogle Scholar
  13. Bowers LD, Canafax DM, Singh J, Seifedlin R, Simmons RL, Najarian JS. Studies of cyclosporine blood levels: analysis, clinical utility, pharmacokinetics, metabolites and chronopharmacology. Transplantation Proceedings 18 (Suppl. 5): 137–143, 1986PubMedGoogle Scholar
  14. Burckart GJ, Venkataramanan R, Ptachcinski RJ, Starzl TE, Gartner JC, et al. Cyclosporine absorption following orthotopic liver transplantation. Journal of Clinical Pharmacology 26: 647–651, 1986PubMedGoogle Scholar
  15. Burke MD, Whiting PH. The role of drug metabolism in cyclosporin A nephrotoxicity. Clinical Nephrology 25 (Suppl. 1): S111–S116, 1986PubMedGoogle Scholar
  16. Busuttil RW, Goldstein LI, Danovitch GM, Ament ME, Memsic LDF. UCLA conference: Liver transplantation today. Annals of Internal Medicine 104: 377–389, 1986PubMedGoogle Scholar
  17. Calne RY, Rolles K, White DJG, Thiru S, Evans DB, et al. Cyclosporin A as initially the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 2: 1033–1036, 1979PubMedGoogle Scholar
  18. Calne RY, White DJG, Thiru S, Evans DB, McMaster P, et al. Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323–1327, 1978PubMedGoogle Scholar
  19. Canafax DM, Cipolle RJ, Hrushesky WJM, Rabatin JT, Min DI, et al. The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplantation Proceedings 20 (Suppl. 2): 471–477, 1988PubMedGoogle Scholar
  20. Cefalu WT, Pardridge WM. Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. Journal of Neurochemistry 45: 1954–1956, 1985PubMedGoogle Scholar
  21. Christians U, Kohlhaw K, Budniak J, Bleck JS, Schottmann R, et al. Ciclosporin metabolite pattern in blood and urine of liver graft recipients I. Association of Ciclosporin metabolites with nephrotoxicity. European Journal of Clinical Pharmacology 41: 285–290, 1991aPubMedGoogle Scholar
  22. Christians U, Schlitt HJ, Bleck JS, Schiebel HM, Kownatzki R, et al. Measurement of cyclosporine and 18 metabolites in blood, bile and urine by high-performance liquid chromatography. Transplantation Proceedings 20 (Suppl. 2): 609–613, 1988PubMedGoogle Scholar
  23. Christians U, Strohmeyer S, Kownatzki R, Schiebel HM, Bleck J, et al. Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile: isolation of 12 new cyclosporine metabolites. Xenobiotica 21: 1185–1198, 1991bPubMedGoogle Scholar
  24. Cipolle RJ, Canafax DM, Rabatin J, Bowers LD, Sutherland DER, et al. Time-dependent disposition of cyclosporine after pancreas transplantation, and application of chronopharmacokinetics to improve immunosuppression. Pharmacotherapy 8: 47–51, 1988PubMedGoogle Scholar
  25. Clardy CW, Schroeder TJ, Myre SA, Wadhwa NK, Pesce AJ, et al. Clinical variability of cyclosporine pharmacokinetics in adult and paediatric patients after renal, cardiac, hepatic and bone marrow transplants. Clinical Chemistry 34: 2012–2015, 1988PubMedGoogle Scholar
  26. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin inducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metabolism and Disposition 17: 197–207, 1989PubMedGoogle Scholar
  27. Consensus Document: Hawk’s Cay meeting on therapeutic drug monitoring of cyclosporine. Transplantation Proceedings 22: 1357–1361, 1990Google Scholar
  28. Copeland KR, Yatscoff RW. Use of a monoclonal antibody for the therapeutic monitoring of cyclosporine in plasma and whole blood. Therapeutic Drug Monitoring 10: 453–458, 1988PubMedGoogle Scholar
  29. De Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clinic Proceedings 63: 1012–1021, 1988PubMedGoogle Scholar
  30. De Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. New England Journal of Medicine 317: 861–866, 1987PubMedGoogle Scholar
  31. Dieperink H, Leyssac PP, Starklint H, Kemp E. Cyclosporine A administration: once a day or in fractional doses?, Transplantation Proceedings 20 (Suppl. 2): 703–706, 1988PubMedGoogle Scholar
  32. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract, British Journal of Clinical Pharmacology 33: 39–43, 1992PubMedGoogle Scholar
  33. Edwards DJ, Ducharme MP, Provenzano R, Smith-Dehoorne M. Effect of grapefruit juice on blood concentrations of cyclosporine. Clinical Pharmacology and Therapeutics 53: 237, 1993Google Scholar
  34. Fahr A, Hiestand P, Ryffel B. Studies on the biological activities of Sandimmun metabolites in humans and in animal models: review and original experiments. Transplantation Proceedings 22: 1116–1124, 1990PubMedGoogle Scholar
  35. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, in press, 1993Google Scholar
  36. Ferguson RM, Rynasiewicz JJ, Sutherland DER, Simmons RL, Najarian JS. Cyclosporin A in renal transplantation: a prospective randomized trial. Surgery 92: 175–182, 1982PubMedGoogle Scholar
  37. First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 2: 1198–1201, 1989PubMedGoogle Scholar
  38. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337: 476–478, 1989PubMedGoogle Scholar
  39. Flechner SM, Katz AR, Rogers AJ, Van Buren C, Kahan BD. The presence of cyclosporine in body tissues and fluids during pregnancy. American Journal of Kidney Diseases 5: 60–63, 1985PubMedGoogle Scholar
  40. Flechner SM, Kolbeinsson ME, Tam J, Lum B. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 47: 806–810, 1989PubMedGoogle Scholar
  41. Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, et al. Intravenous cyclosporine kinetics in renal failure. Clinical Pharmacology and Therapeutics 34: 638–643, 1983PubMedGoogle Scholar
  42. Foxwell BMJ, Frazer G, Winters M, Hiestand P, Wenger R, et al. Identification of cyclophilin as the erythrocyte ciclosporin-binding protein. Biochimica et Biophysica Acta 938: 447–455, 1988PubMedGoogle Scholar
  43. Foxwell BMJ, Mackie A, Ling V, Ryffel B. Identification of the multidrug-resistance related P-glycoprotein as a cyclosporine binding protein. Molecular Pharmacology 36: 543–546, 1989PubMedGoogle Scholar
  44. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. British Journal of Clinical Pharmacology 18: 887–893, 1984PubMedGoogle Scholar
  45. Frey BM, Appenzeller M, Gautschi K, Keller B, Vadas L, et al. Measurements of cyclosporine A by RIA in different centers are not comparable. Transplantation Proceedings 19: 1713–1714, 1987PubMedGoogle Scholar
  46. Frey FJ, Horber FF, Frey BM. Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. Clinical Pharmacology and Therapeutics 43: 55–62, 1988PubMedGoogle Scholar
  47. Gregory CR, Hietala SK, Pedersen NC, Gregory TA, Floyd-Hawkins KA, et al. Cyclosporine pharmacokinetics in cats following topical ocular administration. Transplantation 47: 516–519, 1989PubMedGoogle Scholar
  48. Grevel J. Absorption of cyclosporine A after oral dosing. Transplantation Proceedings 18 (Suppl. 5): 9–15, 1986PubMedGoogle Scholar
  49. Grevel J. Significance of cyclosporine pharmacokinetics. Transplantation Proceedings 20 (Suppl. 2): 428–434, 1988PubMedGoogle Scholar
  50. Grevel J, Kahan BD. Area under the curve monitoring of cyclosporine therapy: the early posttransplant period. Therapeutic Drug Monitoring 13: 89–95, 1991aPubMedGoogle Scholar
  51. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clinical Chemistry 37: 1905–1908, 1991bPubMedGoogle Scholar
  52. Grevel J, Nüesch E, Abisch E, Kutz K. Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. European Journal of Clinical Pharmacology 31: 211–216, 1986PubMedGoogle Scholar
  53. Grevel J, Reynolds KL, Rutzky LP, Kahan BD. Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. Journal of Clinical Pharmacology 29: 261–266, 1989PubMedGoogle Scholar
  54. Gupta SK, Bakran A, Johnson RWG, Rowland M. Erythromycin enhances the absorption of cyclosporin. British Journal of Clinical Pharmacology 25: 401–402, 1988PubMedGoogle Scholar
  55. Gupta SK, Benet LZ. High-fat meals increase the clearance of cyclosporine. Pharmaceutical Research 7: 46–48, 1990PubMedGoogle Scholar
  56. Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Garovoy MR, et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. Journal of Clinical Pharmacology 30: 643–653, 1990PubMedGoogle Scholar
  57. Harfmann P, Dittmer R, Busch R, Tenschert W, Arndt R. Cyclosporin A-induced side effects in renal transplantation are related to the ratio of nonspecific/specific cyclosporine blood trough levels as analysed by radioimmunoassay. Transplantation Proceedings 22: 2369–2372, 1990PubMedGoogle Scholar
  58. Hartman NR, Trimble LA, Vederas JC, Jardine I. An acid metabolite of cyclosporine. Biochimica et Biophysica Acta 133: 964–971, 1985Google Scholar
  59. Hashem H, Venkataramanan R, Burckart GJ, Makowka L, Starzl TE, et al. Identification of the aldehydic metabolites. Transplantation Proceedings 20 (Suppl. 1): 176–178, 1988PubMedGoogle Scholar
  60. Henricsson S. A sulfate conjugate of cyclosporin. Pharmacology and Toxicology 66: 53–55, 1990PubMedGoogle Scholar
  61. Holt DW, Marsden JT, Johnston A, Bewick M, Taube DH. Blood cyclosporin concentrations and renal allograft dysfunction. British Medical Journal 293: 1057–1059, 1986PubMedGoogle Scholar
  62. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J. Metabolic changes in renal transplant patients managed with and without cyclosporin. Clinical Transplantation 6: 403–406, 1992Google Scholar
  63. Johnston A, Holt DW. Cyclosporin radioimmunoassay and cardiac transplantation. Lancet 2: 459, 1988Google Scholar
  64. Johnston A, Marsden JT, Hla KK, Henry J, Holt DW. The effect of vehicle on the oral absorption of cyclosporin. British Journal of Clinical Pharmacology 21: 114P, 1986Google Scholar
  65. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40: 457–476, 1985PubMedGoogle Scholar
  66. Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber MI, van Buren CT. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41: 459–464, 1986PubMedGoogle Scholar
  67. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46: 631–644, 1988PubMedGoogle Scholar
  68. Kahan BD, Ried M, Newburger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplantation Proceedings 15: 446–453, 1983Google Scholar
  69. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. Consensus Document: Hawk’s Cay meeting on therapeutic drug monitoring of cyclosporine. Clinical Chemistry 36: 1510–1516, 1990PubMedGoogle Scholar
  70. Kahan BD, Welsh M, Rutzky L, Lewis R, Knight R, Katz S, et al. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 53: 345–351, 1992PubMedGoogle Scholar
  71. Karlsson MO, Lindberg-Freijs A. Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. Journal of Pharmacokinetics and Biopharmaceutics 18: 293–311, 1990PubMedGoogle Scholar
  72. Kasiske BL, Awni WM, Heim-Duthoy KL, Rose M, Rao VK, et al. Alterations in cyclosporine pharmacokinetics after renal transplantation are linked to rapid increases in hematocrit, lipoproteins, and serum protein. Transplantation Proceedings 20 (Suppl. 2): 485–486, 1988PubMedGoogle Scholar
  73. Keown PA, Stiller CR, Laupacis AL, Howson W, Coles R, et al. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplantation Proceedings 14: 659–661, 1982PubMedGoogle Scholar
  74. Keown PA, Stiller CR, Sinclair NR, Carruthers G, Howson W, et al. The clinical relevance of cyclosporine blood levels as measured by radioimmunoassay. Transplantation Proceedings 15 (Suppl. 1/2): 2438–2441, 1983Google Scholar
  75. Keown PA, Stiller CR, Stawecki M, Freeman D. Pharmacokinetics of cyclosporine in solid organ transplantation. Transplantation Proceedings 18 (Suppl. 5): 160–164, 1986PubMedGoogle Scholar
  76. Keown PA, Stiller CR, Ulan RA, Sinclair NR, Wall WJ, et al. Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet 1: 686–689, 1981PubMedGoogle Scholar
  77. Kessler M, Louis J, Renoult E, Vigneron B, Netter P. Interaction between cyclosporin and erythromycin in a kidney transplant patient. European Journal of Clinical Pharmacology 30: 633–634, 1986PubMedGoogle Scholar
  78. Kivistö KT. A review of assay methods for cyclosporin: clinical implications. Clinical Pharmacokinetics 23: 173–190, 1992PubMedGoogle Scholar
  79. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488–1490, 1991PubMedGoogle Scholar
  80. Koletsky AJ, Harding MW, Handschuhmacher RE. Cyclophilin: distribution and variant properties in normal and neoplastic tissues. Journal of Immunology 137: 1054–1059, 1986Google Scholar
  81. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics 43: 630–635, 1988PubMedGoogle Scholar
  82. Krüger HU, Bross-Bach U, Proksch B, Schmidt H, Dopfer R, et al. A case of accidental cyclosporin overdose with pharmacokinetic analysis. Bone Marrow Transplant 3: 167–169, 1988PubMedGoogle Scholar
  83. Kutz K, Nüesch E, Abisch E, Grevel J. Sandimmun: a study on the relative bioavailability of Sandimmun in normal volunteers (soft gelatine capsules versus an oral solution), Document Sandoz Ltd, March 21, 1985Google Scholar
  84. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy 11: 110S–118S, 1991PubMedGoogle Scholar
  85. Legg B, Rowland M. Cyclosporin: measurement of fraction unbound in plasma. Journal of Pharmacy and Pharmacology 39: 599–603, 1987PubMedGoogle Scholar
  86. Legg B, Rowland M. Saturable binding of Cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment. Pharmaceutical Research 5: 80–85, 1988PubMedGoogle Scholar
  87. LeGrue SJ, Friedman AW, Kahan BD. Binding of cyclosporine by human lymphocytes and phospholipid vesicles. Journal of Immunology 131: 712–718, 1983Google Scholar
  88. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. Journal of Pharmacy and Pharmacology 34: 715–718, 1982PubMedGoogle Scholar
  89. Lensmeyer GL, Wieb DA, Carlson IA. Distribution of cyclosporine A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit and metabolite concentration. Clinical Chemistry 35: 56–63, 1989PubMedGoogle Scholar
  90. Lensmeyer GL, Wiebe DA, Carlson IH, Subramanian R. Concentrations of cyclosporin A and its metabolites in human tissues postmortem. Journal of Analytical Toxicology 15: 110–115, 1991PubMedGoogle Scholar
  91. Lindberg A, Odlind B, Tufveson G, Lindström B, Gabrielsson J. The pharmacokinetics of cyclosporine A in uremic patients. Transplantation Proceedings 18 (Suppl. 5): 144–152, 1986PubMedGoogle Scholar
  92. Lindholm A. Therapeutic monitoring of cyclosporin — an update. European Journal of Clinical Pharmacology 41: 273–283, 1991PubMedGoogle Scholar
  93. Lindholm A, Henricsson S, Dahlqvist R. The effect of food and bile acid administration on the relative bioavailability of cyclosporin. British Journal of Clinical Pharmacology 29: 541–548, 1990PubMedGoogle Scholar
  94. Lindholm A, Henricsson S, Lind M, Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. European Journal of Clinical Pharmacology 34: 461–464, 1988PubMedGoogle Scholar
  95. Lithell H, Odlind B, Selinus I, Lindberg A, Lindström B, et al. Is the plasma lipoprotein pattern of importance for treatment with cyclosporine? Transplantation Proceedings 18: 50–51, 1986Google Scholar
  96. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807–815, 1991PubMedGoogle Scholar
  97. Loertscher R. Cyclosporine-associated nephrotoxicity is not intractable. Transplantation Proceedings 19: 3486–3489, 1987PubMedGoogle Scholar
  98. Lorenz RG, Garrett N, Turk JW, Scott MG. Problems with therapeutic monitoring of cyclosporine using silicone central venous line samples. Transplantation 52: 1109–1110, 1991PubMedGoogle Scholar
  99. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, et al. Cyclosporin toxicity at therapeutic blood levels and cyctochrome P-540 IIIA. Lancet 335: 11–15, 1990PubMedGoogle Scholar
  100. Luke DR, Kasiske BL, Matzke GR, Awni WM, Keane WF. Effects of cyclosporine on the isolated perfused rat kidney. Transplantation 43: 795–799, 1987PubMedGoogle Scholar
  101. Mason J. Renal-side effects of Cyclosporin A. British Journal of Dermatology 122: 71–77, 1990PubMedGoogle Scholar
  102. Maurer G. Metabolism of cyclosporine. Transplantation Proceedings 17 (Suppl. 1): 19–26, 1985PubMedGoogle Scholar
  103. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplantation Proceedings 18 (Suppl. 5): 25–34, 1986PubMedGoogle Scholar
  104. Maurer G, Loosli HR, Schreier E, Keller B. Disposition of cyclosporine in several animal species and man: I. Structural elucidation of its metabolites. Drug Metabolism and Disposition 12: 120–126, 1984PubMedGoogle Scholar
  105. McDonald ML, Ardito T, Marks WH, Kashgarian M, Lorber MI. The effect of cyclosporine administration on the cellular distribution and content of cyclophilin. Transplantation 53: 460–466, 1992PubMedGoogle Scholar
  106. Mehta MU, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Delamos B, et al. Effect of bile on cyclosporin absorption in liver transplant patients. British Journal of Clinical Pharmacology 25: 579–584, 1988PubMedGoogle Scholar
  107. Mihatsch MJ, Thiel G, Ryffel B. Hazards of cyclosporine A therapy and recommendations for its use. Journal of Autoimmunity 1: 533–543, 1988Google Scholar
  108. Morse GD, Holdsworth MT, Venuto RC, Gerbasi J, Walshe JJ. Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. Clinical Pharmacology and Therapeutics 44: 654–664, 1988PubMedGoogle Scholar
  109. Moyer TP, Post GR, Sterioff S, Anderson CF. Cyclosporine nephrotoxity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clinic Proceedings 63: 241–247, 1988PubMedGoogle Scholar
  110. Odlind B, Lindberg A, Tufveson G, Lindström B, Froedin L, et al. Longitudinal study of the pharmacokinetics of cyclosporine before and after renal transplantation. Transplantation Proceedings 18: 47–49, 1986Google Scholar
  111. Oldhafer KJ, Schumann G, Wonigeit K, Oellerich M, Ringe B, et al. Cyclosporine A monitoring by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC) after liver transplantation: influence of route of administration and of liver function on the RIA: HPLC ratio. Transplantation Proceedings 20 (Suppl. 3): 361–365, 1988PubMedGoogle Scholar
  112. Pardridge WM, Triguero D, Yang J, Cancilla PA. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics 253: 884–891, 1990PubMedGoogle Scholar
  113. Perico N, Zoja C, Benigni A, Ghilardi F, Gualandris L, et al. Effect of shortterm cyclosporine administration in rats on reninangiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. Journal of Pharmacology and Experimental Therapeutics 239: 229–235, 1986PubMedGoogle Scholar
  114. Petcher TJ, Weber HP, Rüegger A. Crystal and molecular structure of an iodo derivative of the cyclic undecapeptide cyclosporin A. Helvetica Chimica Acta 59: 1480–1488, 1976PubMedGoogle Scholar
  115. Phillips TM, Karmi SA, Frantz SC, Henriques HF. Absorption profiles of renal allograft recipients receiving oral doses of cyclosporine: a pharmacokinetic study. Transplantation Proceedings 20: 457–461, 1988PubMedGoogle Scholar
  116. Ptachcinski RJ, Burckart GJ, Rosenthal JT, Venkataramanan R, Howrie DL, et al. Cyclosporine pharmacokinetics in children following cadaveric renal transplantation. Transplantation Proceedings 18: 766–767, 1986bGoogle Scholar
  117. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clinical Pharmacokinetics 11: 107–132, 1986aPubMedGoogle Scholar
  118. Ptachcinski RJ, Venkataramanan R, Burckart GJ, Gray JA, van Thiel DH, et al. Cyclosporine kinetics in healthy volunteers. Journal of Clinical Pharmacology 27: 243–248, 1987PubMedGoogle Scholar
  119. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, et al. The effect of food on cyclosporine absorption. Transplantation 40: 174–176, 1985PubMedGoogle Scholar
  120. Reymond JP, Steimer JL, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. Journal of Pharmacokinetics and Biopharmaceutics 16: 331–353, 1988PubMedGoogle Scholar
  121. Reynolds KL, Grevel J, Gibbons SY, Welsh MS, Rutzky LP, et al. Cyclosporine pharmacokinetics in uremic patients: influence of different assay methods. Transplantation Proceedings 20 (Suppl. 2): 462–465, 1988PubMedGoogle Scholar
  122. Ried M, Gibbons S, Kwok D, van Buren CT, Flechner S, et al. Cyclosporine levels in human tissues of patients treated for one week to one year. Transplantation Proceedings 15 (Suppl. 1/2): 2434–2437, 1983Google Scholar
  123. Robinson WT, Schran HF, Barry EP. Methods to measure cyclosporine levels-high pressure liquid chromatography, radioimmunoassay and correlation. Transplantation Proceedings 15 (Suppl. 1/2): 2403–2408, 1983Google Scholar
  124. Rosano TG. Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients, Clinical Chemistry 31: 410–412, 1985PubMedGoogle Scholar
  125. Rosano TG, Freed M, Pell MA, Lempert N. Cyclosporine metabolites in human blood and renal tissue. Transplantation Proceedings 18 (Suppl. 5): 35–40, 1986PubMedGoogle Scholar
  126. Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative HPLC and monoclonal radioimmunoassay studies. Transplantation Proceedings 20 (Suppl. 2): 330–338, 1988PubMedGoogle Scholar
  127. Rosenthaler J, Keller HP. Comment on cyclosporine assay techniques: an attempt for recommendations. Transplantation Proceedings 22: 1160–1165, 1990PubMedGoogle Scholar
  128. Rowland M, Gupta SK. Cyclosporin-phenytoin interaction: Reevaluation using metabolite data. British Journal of Clinical Pharmacology 24: 329–334, 1987PubMedGoogle Scholar
  129. Rüegger A, Kuhn M, Lichti H, Loosli HR, Huguenin R, et al. Cyclosporine A, ein immunsuppressiv wirksamer Peptidmetabolit aus Trichoderma polysporum (Link ex. Pers.) Rifai. Helvetica Chimica Acta 59: 1075–1092, 1976PubMedGoogle Scholar
  130. Ryffel B, Woerly G, Greiner B, Haendler B, Mihatsch MJ, et al. Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology 72: 399–404, 1991PubMedGoogle Scholar
  131. Sandoz AG. Instructions to the Sandimmun Kit, Basel, 1988Google Scholar
  132. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. New England Journal of Medicine 312: 1300–1310, 1985PubMedGoogle Scholar
  133. Schorn T, Kliem V, Bojanovski D, Repp H, Frei U, et al. Long-term immunosuppressive therapy and lipid abnormalities in renal transplant recipients. Nephrology Dialysis Transplantation 3: 581, 1988Google Scholar
  134. Schumacher A, Nordheim A. Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression. Clinical Investigator 70: 773–779, 1992PubMedGoogle Scholar
  135. Schwinghammer TL, Przepiorka D, Venkataramanan R, Wang CP, Burckart GJ, et al. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. British Journal of Clinical Pharmacology 32: 323–328, 1991PubMedGoogle Scholar
  136. Scott JP, Higenbottam TW. Adverse reactions and interactions of Cyclosporin. Medical Toxicology 3: 107–127, 1988PubMedGoogle Scholar
  137. Sgoutas D, Macmahon W, Love A, Jerkunica I. Interaction of cyclosporin A with human lipoproteins. Journal of Pharmacy and Pharmacology 38: 583–588, 1986PubMedGoogle Scholar
  138. Shaw LM, Bowers L, Demers L, Freeman D, Moyer T, et al. Critical issues in cyclosporin monitoring: report of the task force on cyclosporine monitoring. Clinical Chemistry 33: 1269–1288, 1987Google Scholar
  139. Speck RF, Frey FJ, Frey BM. Cyclosporine kinetics in renal transplant patients as assessed by high-performance liquid chromatography and radioimmunoassay using monoclonal and polyclonal antibodies, Transplantation 47: 802–806, 1989PubMedGoogle Scholar
  140. Starzl TE, Weil R, Iwatsuki S, Klintmalm G, Schroeter GPJ, et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surgery Gynecology and Obstetrics 151: 17–26, 1980Google Scholar
  141. Subbarao MN, Swanson JR, Mueggler PA. Cyclosporine determinations in heart and kidney transplant patients: comparison of high-performance liquid chromatography, polyclonal, and monoclonal methods. Therapeutic Drug Monitoring 11: 53–56, 1989PubMedGoogle Scholar
  142. Takada K, Furuya Y, Yoshikawa H, Muranishi S. Biological and pharmaceutical factors affecting the absorption and lymphatic delivery of ciclosporin A from gastrointestinal tract. Journal of Pharmacobio-Dynamics 11: 80–87, 1988PubMedGoogle Scholar
  143. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharmaceutical Research 6: 40–43, 1989PubMedGoogle Scholar
  144. Thiel G, Hermle M, Brunner FP. Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophore side-effect. Clinical Nephrology 25 (Suppl. 1): S40–S42, 1986PubMedGoogle Scholar
  145. Thompson ME, Shapiro AP, Johnsen AM, Itzkoff JM, Hardesty RL, et al. The contrasting effects of cyclosporin A and azathioprine on arterial blood pressure and renal function following cardiac transplantation. International Journal of Cardiology 11: 219–229, 1986PubMedGoogle Scholar
  146. Tjia JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastrointestinal mucosa. British Journal of Clinical Pharmacology 31: 344–346, 1991PubMedGoogle Scholar
  147. Ueda CT, Lemaire M, Gsell G, Nussbaumer K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats. Biopharmaceutics and Drug Disposition 4: 113–124, 1983aGoogle Scholar
  148. Ueda CT, Lemaire M, Misslin P. Pharmacokinetic evaluation of the blood-to-lymph transfer of cyclosporin A in rats. Biopharmaceutics and Drug Disposition 4: 83–94, 1983bGoogle Scholar
  149. Urien S, Zini R, Lemaire M, Tillement JP. Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat. Journal of Pharmacology and Experimental Therapeutics 253: 305–309, 1990PubMedGoogle Scholar
  150. Venkataramanan R, Koneru B, Wang CCP, Burckart GJ, Caritis SN, Starzl TE. Cyclosporine and its metabolites in mother and baby. Transplantation 46: 468–469, 1988bPubMedGoogle Scholar
  151. Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang SL, Starzl TE, et al. The clearance of cyclosporine by hemodialysis. Journal of Clinical Pharmacology 24: 528–531, 1984PubMedGoogle Scholar
  152. Venkataramanan R, Wang CP, Habucky K, Ptachcinski RJ, Burckhart GJ, et al. Species-specific cyclosporine metabolism. Transplantation Proceedings 20 (Suppl. 2): 680–683, 1988aPubMedGoogle Scholar
  153. Venkataramanan R, Yang S, Burckart GJ, Ptachcinski RJ, Van Thiel DH, et al. Diurnal variation in cyclosporine kinetics. Therapeutic Drug Monitoring 8: 380–381, 1986PubMedGoogle Scholar
  154. Vine W, Bowers LD. Cyclosporine: structure, pharmacokinetics and therapeutic drug monitoring. Critical Reviews in Clinical Laboratory Sciences 25: 275–311, 1987PubMedGoogle Scholar
  155. Vine W, Bowers LD. Cyclosporine: assay by HPLC and assay with monoclonal antibodies equivalent? Clinical Chemistry 34: 998, 1988PubMedGoogle Scholar
  156. von Wartburg A, Traber R. Chemistry of the natural cyclosporine metabolites. In Borel JF (Ed.) Progress in allergy, Vol. 38, pp. 28–45, Karger, Basel, 1986Google Scholar
  157. Wadhwa NK, Schroeder TJ, O’Flaherty E, Pesce AJ, Myre SA, et al. The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation 43: 211–213, 1987PubMedGoogle Scholar
  158. Wallemacq PE, Lesne M, Otte JB. Cyclosporine monitoring by RIA and HPLC in liver transplantation: clinical correlation. Clinical Transplantation 1: 132–137, 1987Google Scholar
  159. Wallemacq PE, Lhoest G, Dumont P. Isolation, purification and structure elucidation of cyclosporin A metabolites in rabbit and man. Biomedical and Environmental Mass Spectrometry 18: 48–56, 1989PubMedGoogle Scholar
  160. Wang CP, Burckart GJ, Venkataramanan R, Ptachcinski RJ, Cuellar RE, et al. Cyclosporine metabolite profiles in the blood of liver transplant patients. Transplantation Proceedings 20 (Suppl. 1): 173–175, 1988PubMedGoogle Scholar
  161. Wang PP, Simpson E, Meucci V, Morrison M, Lunetta S, et al. Cyclosporine monitoring by fluorescence polarization immunoassay. Clinical Biochemistry 24: 55–58, 1991PubMedGoogle Scholar
  162. Wassef R, Cohen Z, Langer B. Pharmacokinetic profiles of cyclosporine in rats: influence of route and dose. Transplantation 40: 489–493, 1985PubMedGoogle Scholar
  163. Weiser J, Matha V. The insecticidal activity of cyclosporines on mosquito larvae. Journal of Invertebrate Pathology 51: 92–93, 1988PubMedGoogle Scholar
  164. Wenger RM. Structures of cyclosporine and its metabolites. Transplantation Proceedings 22: 1104–1108, 1990PubMedGoogle Scholar
  165. Wenk M, Follath F, Abisch E. Temperature dependency of apparent cyclosporine A concentrations in plasma. Clinical Chemistry 29: 1865, 1983PubMedGoogle Scholar
  166. Wideman CA. Pharmacokinetic monitoring of cyclosporine, Transplantation Proceedings 15 (Suppl. 1/2): 3168–3175, 1983Google Scholar
  167. Williams GM, Irwin B, Burdick J, Pennington L. Intravenous cyclosporine and kidney function: the Johns Hopkins experience. Transplantation Proceedings 18 (Suppl. 1): 66–68, 1986PubMedGoogle Scholar
  168. Wilms HWF, Straeten V, Lison AE. Different pharmacokinetics of cyclosporine A early and late after renal transplantation. Transplantation Proceedings 20 (Suppl. 2): 481–484, 1988PubMedGoogle Scholar
  169. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clinical Pharmacology and Therapeutics 40: 438–443, 1986aPubMedGoogle Scholar
  170. Yee GC, Kennedy MS, Self SG, Storb R, Deeg HJ. Pharmacodynamics of cyclosporine in patients undergoing bone marrow transplantation. Transplantation Proceedings 18: 774–776, 1986bGoogle Scholar
  171. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Effect of age on cyclosporine pharmacokinetics in marrow transplant recipients. Transplantation Proceedings 19: 1704–1705, 1987PubMedGoogle Scholar
  172. Yee GC, Lennon TP, Gmur DJ, Cheney CL, Oeser D, et al. Effect of obesity on cyclosporine disposition. Transplantation 45: 649–651, 1988aPubMedGoogle Scholar
  173. Yee GC, McGuire TR, Gmur DJ, Lennon TP, Deeg HJ. Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation: influence of age, obesity, and hematocrit. Transplantation 46: 399–402, 1988bPubMedGoogle Scholar
  174. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin. Clinical Pharmacokinetics 19: 319–332 and 400-415, 1990PubMedGoogle Scholar
  175. Ziegler K, Frimmer M, Koepsell H. Photoaffinity labeling of membrane proteins from rat liver and pig kidney with cyclosporine diazirine: involvement of binding to plasma membranes cytotoxic effects. Transplantation 46: 15S–20S, 1988PubMedGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Alfred Fahr
    • 1
  1. 1.Sandoz Pharma LtdBaselSwitzerland
  2. 2.Research & DevelopmentSandoz Pharma LtdBaselSwitzerland

Personalised recommendations